Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Trevi Therapeutics (NASDAQ:TRVI) from a hold rating to a sell rating in a research report report published on Wednesday morning, Zacks.com reports.

According to Zacks, “Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson’s disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut. “

Several other equities analysts have also recently commented on the stock. BMO Capital Markets began coverage on shares of Trevi Therapeutics in a research report on Monday, June 3rd. They set an outperform rating and a $15.00 target price on the stock. Needham & Company LLC began coverage on shares of Trevi Therapeutics in a research report on Monday, June 3rd. They set a buy rating and a $18.00 target price on the stock. Leerink Swann began coverage on shares of Trevi Therapeutics in a research report on Monday, June 3rd. They set an outperform rating on the stock. Stifel Nicolaus began coverage on shares of Trevi Therapeutics in a research report on Monday, June 3rd. They set a buy rating and a $20.00 target price on the stock. Finally, Svb Leerink began coverage on shares of Trevi Therapeutics in a research report on Monday, June 3rd. They set an outperform rating and a $14.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $16.75.

Trevi Therapeutics stock opened at $4.80 on Wednesday. Trevi Therapeutics has a 52 week low of $4.04 and a 52 week high of $10.62. The business’s 50 day moving average price is $5.94.

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $26,000. Morgan Stanley bought a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $42,000. Northern Trust Corp bought a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $124,000. Vanguard Group Inc. bought a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $886,000. Finally, Omega Fund Management LLC bought a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $9,476,000. 36.50% of the stock is currently owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

Featured Article: Strike Price

Get a free copy of the Zacks research report on Trevi Therapeutics (TRVI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ark  Price Reaches $0.23 on Major Exchanges
Ark Price Reaches $0.23 on Major Exchanges
BitRewards Hits 1-Day Trading Volume of $47.00
BitRewards Hits 1-Day Trading Volume of $47.00
Brokerages Expect Comerica Incorporated  Will Announce Quarterly Sales of $839.87 Million
Brokerages Expect Comerica Incorporated Will Announce Quarterly Sales of $839.87 Million
$2.44 Billion in Sales Expected for Newell Brands Inc  This Quarter
$2.44 Billion in Sales Expected for Newell Brands Inc This Quarter
WP Carey  Downgraded by Zacks Investment Research
WP Carey Downgraded by Zacks Investment Research
Tortoise Capital Advisors L.L.C. Grows Stake in Delek Logistics Partners LP
Tortoise Capital Advisors L.L.C. Grows Stake in Delek Logistics Partners LP


 
© 2006-2019 Zolmax.